Eli Lilly’s weight loss drug Zepbound found to reduce sleep apnea, company says

  • 📰 NBCNewsHealth
  • ⏱ Reading Time:
  • 21 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 51%

News News

Business Business Latest News,Business Business Headlines

Berkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.

Eli Lilly’s weight loss drug Zepbound was found to reduce obstructive sleep apnea in adults with obesity, the drugmaker said in a release Wednesday. Obstructive sleep apnea affects about 39 million adults in the U.S., according to the National Council on Aging. It occurs when a person’s upper airway becomes blocked during sleep, cutting off airflow throughout the night, the National Heart, Lung and Blood Institute says. Obesity, which can narrow the airway, can increase a person's risk.

The researchers found that after 52 weeks, Zepbound had led to an average reduction of 27.4 events per hour in people who were not on PAP machines, compared to a reduction of 4.8 events per hour for people on the placebo. In people who did use PAP machines, Zepbound led to an average reduction of 30.4 events per hour, compared to an average reduction of 6 events per hour for the placebo group. Dr.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 707. in BUSİNESS

Business Business Latest News, Business Business Headlines